These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 27382257)

  • 1. Fondaparinux vs warfarin for the treatment of unsuspected pulmonary embolism in cancer patients.
    Amato B; Compagna R; Rocca A; Bianco T; Milone M; Sivero L; Vigliotti G; Amato M; Danzi M; Aprea G; Gallelli L; de Franciscis S; Serra R
    Drug Des Devel Ther; 2016; 10():2041-6. PubMed ID: 27382257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multidetector-row computed tomography-based clinical assessment of fondaparinux for treatment of acute pulmonary embolism and acute deep vein thrombosis in Japanese patients.
    Nakamura M; Okano Y; Minamiguchi H; Munemasa M; Sonoda M; Yamada N; Hanzawa K; Aoyagi N; Tsujimoto H; Sarai N; Nakajima H; Kunieda T
    Circ J; 2011; 75(6):1424-32. PubMed ID: 21512258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism.
    Büller HR; Davidson BL; Decousus H; Gallus A; Gent M; Piovella F; Prins MH; Raskob G; van den Berg-Segers AE; Cariou R; Leeuwenkamp O; Lensing AW;
    N Engl J Med; 2003 Oct; 349(18):1695-702. PubMed ID: 14585937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Possible failure of novel direct-acting oral anticoagulants in management of pulmonary embolism: a case report.
    Rankin J; Nagar M; Crosby J; Toomari N; Pietras R; Ben-Zur UM
    J Med Case Rep; 2016 Dec; 10(1):346. PubMed ID: 27912791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fondaparinux vs warfarin for the treatment of unsuspected pulmonary embolism in cancer patients.
    Abdel-Razeq H; Mansour A
    Drug Des Devel Ther; 2016; 10():2677-9. PubMed ID: 27601884
    [No Abstract]   [Full Text] [Related]  

  • 6. Fondaparinux as alternative anticoagulant to warfarin or low-molecular-weight heparin for recurrent venous thrombosis.
    Thachil J
    Ann Pharmacother; 2014 Mar; 48(3):420-4. PubMed ID: 24473488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
    van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
    Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention.
    Huisman MV; Bounameaux H
    Semin Vasc Med; 2005 Aug; 5(3):276-84. PubMed ID: 16123915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylaxis of catheter-related deep vein thrombosis in cancer patients with low-dose warfarin, low molecular weight heparin, or control: a randomized, controlled, phase III study.
    Lavau-Denes S; Lacroix P; Maubon A; Preux PM; Genet D; Vénat-Bouvet L; Labourey JL; Martin J; Slaouti P; Tubiana-Mathieu N
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):65-73. PubMed ID: 23636449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The treatment of deep venous thrombosis, including the newer agents.
    Rectenwald JE; Wakefield TW
    Dis Mon; 2005; 51(2-3):104-11. PubMed ID: 15900261
    [No Abstract]   [Full Text] [Related]  

  • 11. Superiority of fondaparinux over enoxaparin in preventing venous thromboembolism in major orthopedic surgery using different efficacy end points.
    Turpie AG; Bauer KA; Eriksson BI; Lassen MR
    Chest; 2004 Aug; 126(2):501-8. PubMed ID: 15302737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fondaparinux for prevention of venous thromboembolism in high-risk trauma patients: a pilot study.
    Lu JP; Knudson MM; Bir N; Kallet R; Atkinson K
    J Am Coll Surg; 2009 Nov; 209(5):589-94. PubMed ID: 19854398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fondaparinux for the treatment of superficial-vein thrombosis in the legs.
    Decousus H; Prandoni P; Mismetti P; Bauersachs RM; Boda Z; Brenner B; Laporte S; Matyas L; Middeldorp S; Sokurenko G; Leizorovicz A;
    N Engl J Med; 2010 Sep; 363(13):1222-32. PubMed ID: 20860504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial.
    Cohen AT; Davidson BL; Gallus AS; Lassen MR; Prins MH; Tomkowski W; Turpie AG; Egberts JF; Lensing AW;
    BMJ; 2006 Feb; 332(7537):325-9. PubMed ID: 16439370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial.
    Fiessinger JN; Huisman MV; Davidson BL; Bounameaux H; Francis CW; Eriksson H; Lundström T; Berkowitz SD; Nyström P; Thorsén M; Ginsberg JS;
    JAMA; 2005 Feb; 293(6):681-9. PubMed ID: 15701909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deep venous thrombosis and pulmonary embolism. Part 2--Prevention of recurrences: warfarin or low-molecular-weight heparin for at least 3 months.
    Prescrire Int; 2013 May; 22(138):129-33. PubMed ID: 23819181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fondaparinux in the initial and long-term treatment of venous thromboembolism.
    Pesavento R; Amitrano M; Trujillo-Santos J; Di Micco P; Mangiacapra S; López-Jiménez L; Falgá C; García-Bragado F; Piovella C; Prandoni P; Monreal M;
    Thromb Res; 2015 Feb; 135(2):311-7. PubMed ID: 25543161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dabigatran (Pradaxa): deep vein thrombosis and pulmonary embolism. Warfarin remains the standard drug.
    Prescrire Int; 2015 Jun; 24(161):150. PubMed ID: 26436165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial.
    Büller HR; Gallus AS; Pillion G; Prins MH; Raskob GE;
    Lancet; 2012 Jan; 379(9811):123-9. PubMed ID: 22130488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of current and emerging antithrombotics in thrombosis and cancer.
    Mousa SA
    Drugs Today (Barc); 2006 May; 42(5):331-50. PubMed ID: 16801996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.